Literature DB >> 27837025

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.

Mark W Richards1,2, Selena G Burgess1,2, Evon Poon3, Anne Carstensen4,5,6, Martin Eilers4,5,6, Louis Chesler3, Richard Bayliss7,2,8.   

Abstract

Myc family proteins promote cancer by inducing widespread changes in gene expression. Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosphorylation of Myc Box I and ubiquitination by the E3 ubiquitin ligase SCFFbxW7 However, N-Myc protein (the product of the MYCN oncogene) is stabilized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds SCFFbxW7 We determined the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-Å resolution. The structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD532 is not compatible with the binding of N-Myc, explaining the activity of these compounds in neuroblastoma cells and providing a rational basis for the design of cancer therapeutics optimized for destabilization of the complex. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCFFbxW7 to disfavor the generation of Lys48-linked polyubiquitin chains.

Entities:  

Keywords:  Aurora-A kinase; Myc; neuroblastoma; protein–protein interaction; structural biology

Mesh:

Substances:

Year:  2016        PMID: 27837025      PMCID: PMC5137718          DOI: 10.1073/pnas.1610626113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.

Authors:  Laura A Jaenicke; Björn von Eyss; Anne Carstensen; Elmar Wolf; Wenshan Xu; Ann Katrin Greifenberg; Matthias Geyer; Martin Eilers; Nikita Popov
Journal:  Mol Cell       Date:  2015-12-10       Impact factor: 17.970

Review 2.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

3.  A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants.

Authors:  Antonio Pineda-Lucena; Cynthia S W Ho; Daniel Y L Mao; Yi Sheng; Rob C Laister; Ranjith Muhandiram; Ying Lu; Bruce T Seet; Sigal Katz; Thomas Szyperski; Linda Z Penn; Cheryl H Arrowsmith
Journal:  J Mol Biol       Date:  2005-08-05       Impact factor: 5.469

Review 4.  Taming of the beast: shaping Myc-dependent amplification.

Authors:  Elmar Wolf; Charles Y Lin; Martin Eilers; David L Levens
Journal:  Trends Cell Biol       Date:  2014-12-01       Impact factor: 20.808

5.  Drugging MYCN through an allosteric transition in Aurora kinase A.

Authors:  William Clay Gustafson; Justin Gabriel Meyerowitz; Erin A Nekritz; Justin Chen; Cyril Benes; Elise Charron; Erin F Simonds; Robert Seeger; Katherine K Matthay; Nicholas T Hertz; Martin Eilers; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2014-08-28       Impact factor: 31.743

6.  Transposition and amplification of oncogene-related sequences in human neuroblastomas.

Authors:  N E Kohl; N Kanda; R R Schreck; G Bruns; S A Latt; F Gilbert; F W Alt
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.

Authors:  M M Nau; B J Brooks; J Battey; E Sausville; A F Gazdar; I R Kirsch; O W McBride; V Bertness; G F Hollis; J D Minna
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

8.  Decision making in xia2.

Authors:  Graeme Winter; Carina M C Lobley; Stephen M Prince
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-18

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  54 in total

Review 1.  Polyamine synthesis as a target of MYC oncogenes.

Authors:  André S Bachmann; Dirk Geerts
Journal:  J Biol Chem       Date:  2018-11-07       Impact factor: 5.157

Review 2.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

3.  Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Authors:  Steven G DuBois; Yael P Mosse; Elizabeth Fox; Rachel A Kudgus; Joel M Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M Maris; Clare J Twist; Kelly Goldsmith; M Meaghan Granger; Brian Weiss; Julie R Park; Margaret E Macy; Susan L Cohn; Greg Yanik; Lars M Wagner; Randall Hawkins; Jesse Courtier; Hollie Lai; Fariba Goodarzian; Hiroyuki Shimada; Najee Boucher; Scarlett Czarnecki; Chunqiao Luo; Denice Tsao-Wei; Katherine K Matthay; Araz Marachelian
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

4.  Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Authors:  Kevin Campbell; Derek Shyr; Rochelle Bagatell; Matthias Fischer; Akira Nakagawara; Adela Canete Nieto; Garrett M Brodeur; Katherine K Matthay; Wendy B London; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2019-05-21       Impact factor: 3.167

Review 5.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

6.  Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction.

Authors:  Jonathan D Macdonald; Selena Chacón Simon; Changho Han; Feng Wang; J Grace Shaw; Jennifer E Howes; Jiqing Sai; Joannes P Yuh; Demarco Camper; Bethany M Alicie; Joseph Alvarado; Sameer Nikhar; William Payne; Erin R Aho; Joshua A Bauer; Bin Zhao; Jason Phan; Lance R Thomas; Olivia W Rossanese; William P Tansey; Alex G Waterson; Shaun R Stauffer; Stephen W Fesik
Journal:  J Med Chem       Date:  2019-12-05       Impact factor: 7.446

7.  Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

Authors:  Jiaoyang Cai; Ci Pan; Yanjing Tang; Jing Chen; Min Zhou; Benshang Li; Huiliang Xue; Shuhong Shen; Yijin Gao; AnAn Zhang; Jingyan Tang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-11       Impact factor: 4.553

Review 8.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

9.  MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.

Authors:  Qin Tong; Shuming Ouyang; Rui Chen; Jie Huang; Linlang Guo
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 10.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.